Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Daniel Eisman

Vascular & Interventional Radiology Teaneck, NJ Medical Doctor

NPI 1740635036 CMS profile 4701357

718 Teaneck Rd, Teaneck, NJ 07666

Open in the dashboard

General payments

$3,908

71 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Eisman of Teaneck, NJ is reported in the CMS Open Payments database as having received $3,908 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,570 19
2024 General $602 32
2023 General $528 7
2022 General $671 6
2021 General $390 4
2020 General $147 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Eisman
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Daniel Eisman were reported at $1,570. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Daniel Eisman Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $147 $200 $68–$652 $114
2021 $390 $280 $99–$866 $132
2022 $671 $433 $137–$1,497 $149
2023 $528 $506 $152–$2,019 $160
2024 $602 $556 $175–$1,930 $164
2025 $1,570 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Atrium Medical Corporation $1,000 1 payment
  2. Inari Medical, Inc. $610 5 payments
  3. Terumo Medical Corporation $346 4 payments
  4. Abbott Laboratories $299 4 payments
  5. Ethicon US, LLC $258 3 payments
  6. Sirtex Medical Inc $188 4 payments
  7. Shockwave Medical, Inc $186 6 payments
  8. Medtronic, Inc. $181 21 payments
  9. Penumbra, Inc. $176 4 payments
  10. Stryker Corporation $163 6 payments
  11. Other $500 13 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $2,681 69 payments
  2. Consulting Fee $1,000 1 payment
  3. Education $227 1 payment
Products named General payments · program years 2020–2025
  1. FLOWTRIEVER CATHETER, S $610 5 payments
  2. CT THROMBECTOMY SYSTEM KIT $610 5 payments
  3. PERCLOSE PROGLIDE $292 3 payments
  4. Neuwave $258 3 payments
  5. SIR-Spheres Microspheres $188 4 payments
  6. Ruby $147 3 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $143 4 payments
  8. ENROUTE Transcarotid Neuroprotection System $139 1 payment
  9. ARGYLE $119 1 payment
  10. Azur CX Detachable $92 2 payments
  11. Other $817 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 160 billing codes

Paid by Medicare

$90,367

Of which drugs: $635

Medicare patients

578

Average age 75

Services billed

6,993

324 women, 254 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 51%
Ischemic heart disease 45%
Chronic kidney disease 39%
Heart failure 36%
Atrial fibrillation 29%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 58 5,900 $635

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record